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Abstract
Aims Membrane-bound angiotensin-converting enzyme (ACE)2 is the main cellular access point for SARS-CoV-2, but its ex-
pression and the effect of ACE inhibition have not been assessed quantitatively in patients with heart failure. The aim of this
study was to characterize membrane-bound ACE2 expression in the myocardium and myocardial vasculature in patients un-
dergoing heart transplantation and to assess the effect of pharmacological ACE inhibition.
Methods and results Left ventricular (LV) tissue was obtained from 36 explanted human hearts from patients undergoing
heart transplantation. Immunohistochemical staining with antibodies directed against ACE2 co-registered with cardiac tropo-
nin T (cTnT) and α-smooth muscle cell actin (SMA) was performed across the entire cohort. ACE2 receptor expression was
quantitatively assessed throughout the myocardium and vasculature. ACE2 was consistently expressed throughout the LV
myocardium (28.3% ± 22.2% of cardiomyocytes). ACE2 expression was also detected in small calibre blood vessels (range,
2–9 μm), albeit at quantitatively much lower levels (5% ± 9% of blood vessels). There was no significant difference in ACE2
expression between patients receiving ACE inhibitors prior to transplantation and ACE inhibitor-negative controls
(P > 0.05). ACE2 expression did not differ significantly between the different diagnostic groups as the underlying reason
for heart transplantation (ANOVA > 0.05). N-terminal pro-brain natriuretic peptide (NT-proBNP) (R2 = 0.37, P = 0.0006) and
pulmonary capillary wedge pressure (PCWP) (R2 = 0.13, P = 0.043) assessed by right heart catheterization were significantly
correlated with greater ACE2 expression in cardiomyocytes.
Conclusions These data provide a comprehensive characterization of membrane-bound cardiac ACE2 expression in patients
with heart failure with no demonstrable effect exerted by ACE inhibitors.
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Introduction
Angiotensin-converting enzyme 2 (ACE2) serves as a key
counter-regulator of the renin–angiotensin aldosterone sys-
tem (RAAS). Decreased levels of ACE2 increase susceptibility
to heart failure driven by the fibrotic, oxidative and pro-in-
flammatory effects of the Ang II/AT1R axis, whereas increased
ACE2 levels counterbalance these effects via the conversion
of Ang II to Ang 1–7, imparting protection against heart
failure.1 At the same time, membrane-bound ACE2 and its ac-
cessory protease TMPRSS2 serve as the main cellular entry
points for SARS-CoV-2, making them key determinants of dis-
ease susceptibility.2,3
In the wake of the first global COVID-19 wave, concerns
were raised as to the safety of ACE inhibitors and angiotensin
receptor blockers (ARBs), because preclinical data demon-
strated that these drugs result in increased ACE2
expression.4–6 However, clinical studies have since shown
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that their use is safe in patients with COVID-19 and does not
result in increased disease susceptibility.7–10 Indeed, ACE in-
hibitors and ARBs may exert protective effects as ACE2 is re-
duced in COVID-19, resulting in unopposed detrimental
action of AngII on the lungs.11
Cardiovascular complications occur in 20%–30% of pa-
tients critically ill with COVID-19 and are harbingers of a com-
plicated disease trajectory.12,13 If the cardiovascular system is
involved in the disease process, medical treatment can be
complicated by cardiac arrhythmias, heart failure and myo-
cardial injury.12,14 One mechanism of myocardial injury is
thought to be direct viral myocarditis, with ACE2 mediating
viral entry. This is corroborated by in vitro studies and limited
evidence from post-mortem examinations as well as clinical
studies investigating endomyocardial biopsies, demonstrating
the presence of the SARS-CoV-2 genome in the
myocardium.15–18
Despite the safety of ACE inhibitors and ARB use in large
cohorts of patients with COVID-19, specific subgroups of pa-
tients with particularly high cardiac ACE2 expression may be
at increased risk of myocarditis if pharmacological ACE inhibi-
tion use further increases cardiac membrane-bound ACE2
levels. In heart failure, it has been demonstrated that soluble
ACE2 levels are increased, but there is a paucity of data on
the effects of ACE inhibitors on the expression of
membrane-bound cardiac ACE2 in heart failure.19 Indeed,
most data on cardiac ACE2 protein expression come from ro-
dents, demonstrating expression in cardiomyocytes, smooth
muscle cells, endothelial cells and cardiac fibroblasts.20–22
In non-diseased human hearts, single-cell sequencing has
demonstrated that 6.6% of cardiomyocytes express ACE2.23
Single-nucleus RNA sequencing of human hearts has shown
increased ACE2 expression in cardiomyocytes and decreased
expression in pericytes, smooth muscle cells and fibroblasts
of patients with dilated cardiomyopathy and hypertrophic
cardiomyopathy compared with normal hearts.24 In line with
these findings, bulk sequencing of failing hearts has demon-
strated increased ACE2 mRNA expression and increased pro-
tein expression compared with non-diseased hearts.25
However, major drawbacks of such transcriptional measure-
ments include that they do not take into account RNA half-
life, translation efficacy or protein turnover. This highlights
that studies investigating membrane-bound ACE2 protein
are essential, particularly in vulnerable groups.
Here, we demonstrate the quantitative assessment of
ACE2 expression across the explanted left ventricular (LV)
myocardial tissues of 36 heart transplant recipients. We elu-
cidate expression in cardiomyocytes and the blood vascula-
ture and assess the effect of ACE inhibitor administration
prior to transplantation. Furthermore, we provide corollary
data on clinical characteristics and myocardial ACE2 receptor
expression. These data serve as an important source of
validation for sequencing studies and broaden the current
insight into ACE2 expression in human hearts.
Methods
Study design and population
This study was designed to investigate the expression of ACE2
receptor expression across explanted human hearts and de-
termine the effect of pharmacological ACE inhibition. The
study design is depicted in Figure 1A. Tissues from explanted
hearts of 36 patients who underwent heart transplantation at
Royal Papworth Hospital for end-stage heart failure between
5 August 2013 and 28 December 2018 were sourced from the
Royal Papworth Hospital tissue bank. Cases were selected if
4% formalin-fixed and paraffin-embedded LV tissue blocks
were available. Cases were classified as dilated cardiomyopa-
thy (DCM), hypertrophic cardiomyopathy (HCM), ischaemic
cardiomyopathy (ICM) or arrhythmogenic cardiomyopathy
(ACM) and were categorized into ACE inhibitor administra-
tion present or absent based on the history. Cases with a
more recent inclusion date were selected first. We attempted
to select an equal number of cases established on ACE inhib-
itors and ACE inhibitor-negative controls. Equally we included
the same number of cases per underlying cardiac aetiology in
the ACE inhibitor groups and the ACE inhibitor-negative con-
trol group.
The clinical baseline characteristics of the cohort are
shown in Table 1. Tissue blocks were sectioned, and immuno-
histochemistry, imaging, quantification and statistical analysis
were performed. The only exclusion criterion was administra-
tion of ARBs as this is a potential confounder of ACE2 recep-
tor expression. Ethical approval to provide human tissue for
research was granted to the Royal Papworth Hospital (RPH)
Research Tissue Bank by the East of England—Cambridge East
Research Ethics Committee (REC reference: 18/EE/0269). Par-
ticipants whose explanted hearts were donated to the RPH
tissue bank had provided written, informed consent.
Tissue processing and immunohistochemistry
LV tissues were consistently collected from the lateral free
wall, fixed in 4% paraformaldehyde, paraffin-embedded, sec-
tioned and additionally wax-dipped to optimize preservation.
For immunohistochemistry, slides were dewaxed for 20 min
at 60°C and subsequently deparaffinized, before being sub-
ject to heat-mediated antigen retrieval with citric acid buffer
for 10 min with pH optimized at 6 as previously described.26
Slides were subsequently blocked with 5% BSA/PBS contain-
ing 0.3% Triton X-100 for 1 h at room temperature. This
was followed by incubation with primary antibodies at 4°C
overnight and application of fluorescent secondary antibod-
ies at room temperature for 60 min on the consecutive day.
A detailed description of the antibodies and dilutions used
is provided in Table S1.
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Imaging
All qualitative images shown were acquired on a Leica SP5
confocal microscope using Leica imaging software. For
quantitative image analysis, three representative images
were acquired across all 36 patients on an EVOS FL digital
inverted microscope (Life Technologies) for both
ACE2/cTnT and ACE2/α-smooth muscle cell actin (SMA)
co-staining.
Quantification and validation
Image quantification was performed with ImageJ. For quan-
tification of ACE receptor expression across the myocar-
dium, sections stained with antibodies directed against
ACE2 and cTnT were imported, and the number of
cardiomyocytes was manually counted, followed by
counting of ACE2-positive cardiomyocytes for which preset
rules were applied. Cells were identified as cardiomyocytes
Figure 1 Visualization of Covid19 binding sites by ACE2 receptor expression. (A) Schematic of study design. Heart explant sections were obtained from
36 patients undergoing heart transplantation. Paraffin-embedded sections were stained for cTnT/ACE2 and SMA/ACE2 across the entire cohort. The
results were subsequently correlated with pretransplant characteristics. (B) Validation of ACE2 antibodies. Expression of ACE2 in human left ventricular
myocardium. Scale bars: 25 and 10 μm, respectively. (C) IgG Isotype control for ACE2, demonstrating specificity of staining. Scale bar, 25 μm. (D) Ex-
pression of the accessory protease TMPRSS2 and ACE2, demonstrating co-expression in a subset of cardiomyocytes. Scale bars: 25 and 10 μm, respec-
tively. (E) IgG Isotype control for TMPRSS2, demonstrating specificity of staining. Scale bar: 25 μm.Abbreviations: LV, left ventricular; ACE2,
angiotensin-converting enzyme 2; cTnT, cardiac muscle troponin T; IgG, immunoglobulin G.
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Table 1 Baseline characteristics of 36 patients undergoing heart transplantation
Variable All Patients (n = 36)
Age, years, mean ± SD 51 ± 13 (54; 18–82)
Male, sex, n (%), male 26 (72%)
Race, n (%)
White—British 32 (89%)
Black or black British 2 (6%)
Any other ethnic background 2 (6%)
Underlying diagnosis for HTx, n (%)
Hypertrophic cardiomyopathy 12 (33%)
Dilated cardiomyopathy 8 (22%)
Ischaemic heart disease 8 (22%)
Arrhythmogenic cardiomyopathy 8 (22%)
Listing state, n (%)
Non-urgent 17 (49%)
Urgent 18 (51%)
NYHA functional class, n (%)
NYHA 1 1 (4%)
NYHA 2 1 (4%)
NYHA 3 21 (75%)
NYHA 4 5 (18%)
6MWT distance (m), mean ± SD 314.1 ± 96.9 (336; 140–452)
CPEX  VO2max (mL/kg/min), mean ± SD 14.3 ± 7.01 (12.2; 5.8–40)
ECG, n (%)
QRS > 120 ms 19 (53%)
LBBB 4 (11%)
RBBB 6 (17%)
Inotropic support, n (%) 11 (31%)
Device therapy, n (%) 27 (75%)
ICD 17 (47%)
BiV pacemaker 7 (19%)





Coexisting disorders and interventions, n (%)
Hypertension 6 (17%)
Diabetes 7 (19%)
Atrial fibrillation 18 (50%)
Atrial flutter 7 (19%)
Stroke 6 (17%)
Coronary artery disease 3 (8.3%)
Myocardial infarction 8 (23%)
Previous PCI 6 (17%)
Previous CABG 2 (6%)
COPD 2 (6%)
Chronic lung disease 4 (11%)
Active smoker 4 (11%)
Chronic renal disease 8 (22%)
Pretransplant cardiovascular drug therapy, n (%)
ACE inhibitor 19 (53%)
Time on ACE inhibitor (days) 570 ± 768 (349; 47 to 3,073)
Beta-blockade 25 (70%)




Physiologic parameters prior to HTx, mean ± SD
Right heart catheter
PCWP (mmHg) 17 ± 6.3 (17.5; 1–28)
RA pressure (mmHg) 11.2 ± 6.5 (10; 1–26)
CI (l/min/m2) 1.69 ± 0.42 (1.6; 1.1–2.8)
Echo
LVEF (%) 27.5 ± 15.2 (20; 6–60)
TAPSE (mm) 14.3 ± 4.3 (14; 6.1–25)
sPAP (mmHg) 39 ± 17.9 (40; 1–77)
LVESD (mm) 40.4 ± 16 (38; 4.7–71)
(Continues)
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Table 1 (continued)
Variable All Patients (n = 36)
LVEDD (mm) 54.3 ± 14.9 (56; 5.6–79)
Laboratory data, mean ± SD
NT-proBNP (pg/mL) 4,453 ± 3,155 (3,355; 157–12,444)
Serum creatinine (μmol/L) 119 ± 35 (111.5; 58–189)
Na (mmol/L) 137.4 ± 4.2 (138; 125–143)
Hb (g/L) 120 ± 43 (130; 12.7–159)
Bilirubin (μmol/L) 23.69 ± 12.8 (20; 7–62)
ALT (U/L) 50.2 ± 61.5 (37; 18–345)
Albumin (g/L) 61.58 ± 79.2 (42.5; 35–436)
6MWT, 6-min walk test; ALT, alanine aminotransferase. BiV, biventricular; CABG, coronary artery bypass grafting; CI, cardiac index; COPD,
chronic obstructive lung disease; CPEX, cardiopulmonary exercise testing; ECMO, extracorporeal membrane oxygenation; Hb,
haemoglobin; ICD, implantable cardioverter defibrillator; LBBB, left bundle branch block; LVAD, left ventricular assist device; LVEDD, left
ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic dimension; NT-pro BNP,
N-terminal prohormone of brain natriuretic peptide; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; PCWP,
pulmonary capillary wedge pressure; RA, right atrial; RBBB, right bundle branch block; SPAP, systolic pulmonary artery pressure; TAPSE,
tricuspid annular plane systolic excursion.
Figure 2 Quantification of myocardial ACE2 expression in explanted human hearts.(A) ACE2 expression in human cardiomyocytes in explanted hearts.
Scale bar: 25 μm. (B) Quantification of ACE2 expression expressed as % of ACE2-positive cardiomyocytes of all cardiomyocytes. Bottom pie chart shows
group stratification. (C) ACE2 expression in patients according to underlying reason for heart transplantation. HCM, hypertrophic cardiomyopathy; ICM,
ischaemic cardiomyopathy; ACM, arrhythmogenic cardiomyopathy; DCM, dilated cardiomyopathy. (D) Effect of ACE inhibitor administration on ACE2
expression. (E) Baseline clinical variables significantly correlated with myocardial ACE2 expression. Shown is NT-proBNP. (F) Correlation of PCWP
(mmHg) with myocardial ACE2 expression.Abbreviations: ACE2, angiotensin-converting enzyme 2; cTnT, cardiac muscle troponin T; IgG, immunoglob-
ulin G.
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if a nucleus could be clearly attributed to the surrounding
cTnT signal. Binucleated cells were counted as one cardio-
myocyte. All cardiomyocytes were counted on all 108 im-
ages (three technical replicates per patient) amounting to
10 707 cardiomyocytes identified in total. If there was ex-
pression of ACE2 in previously identified cardiomyocytes,
this was expressed as ACE2 + cardiomyocytes (% of all
cardiomyocytes identified). For quantification of ACE2 ex-
pression across the vasculature, sections stained with anti-
bodies directed against ACE2 and SMA were analysed.
Structures with a clearly identifiable lumen and SMA positiv-
ity were identified as blood vessels and numerically
assessed. The number of ACE2 expressing blood vessels
was counted, and the diameter of ACE2 positive blood ves-
sels was measured. Figures 2B and 3B show a circular
heatmap displaying a group stratification based on the %
of cardiomyocytes and % of blood vessels, respectively, ac-
counting for ACE2 expression, and show the number of pa-
tients falling into each group. Table S2 shows all clinical
characteristics correlated with ACE2 expression in
cardiomyocytes and blood vessels, respectively.
All images were anonymized, and a primary reader made
measurements in a blinded manner. For validation purposes,
a sample set of images was analysed by an independent
Figure 3 Quantification of vascular ACE2 expression in explanted human hearts.(A) ACE2 and SMA co-expression in blood vasculature of explanted
human hearts. White arrows indicate co-expression. Scale bars: 25 and 10 μm, respectively. (B) Quantification of ACE2 expression expressed as %
of ACE2-positive blood vessels of all blood vessels. Bottom pie chart shows group stratification. (C) Average vessel diameter in μm in ACE2+/SMA+
patients. (D) ACE2 and CD31 co-expression in blood vasculature of explanted human hearts. White arrow indicates co-expression. (E) Vascular ACE2
expression in patients according to underlying reason for heart transplantation. HCM, hypertrophic cardiomyopathy; ICM, ischaemic cardiomyopathy;
ACM, arrhythmogenic cardiomyopathy; DCM, dilated cardiomyopathy. (F) Effect of ACE inhibitor administration on ACE2 expression in blood vascula-
ture.Abbreviations: SMA, alpha smooth muscle actin; ACE2, angiotensin-converting enzyme 2; CD31, cluster of differentiation 31; ACEi,
angiotensin-converting enzyme inhibitor.
6 J. Bargehr et al.
ESC Heart Failure (2021)
DOI: 10.1002/ehf2.13528
investigator in a blinded fashion to ensure reproducibility in
measurements. The respective Bland–Altman plots and
intraclass correlation coefficients of these two tests are
presented in Figure S1.
Statistical analysis
All analysis of quantitatively acquired images was performed
in three technical replicates per patient (i.e. three images per
patient). All experimental data specifically state the number
of patients assessed for quantitative endpoint analysis. The
normal distribution of our values was confirmed using the
D’Agostino and Pearson omnibus normality test where appro-
priate. Statistical testing was performed using an unpaired t-
test for two-group comparisons, and a one-way ANOVA with
a post hoc Tukey test was used for multiple-group compari-
son. Measuring two-sided significance, a P-value of 0.05
was considered statistically significant. All analyses were per-
formed using GraphPad Prism software in a blinded fashion.
All results are expressed as mean ± SD (median; min to
max), unless otherwise stated.
Results
Study population
A total of 36 patients who underwent heart transplantation
between August 2013 and December 2018 for end-stage
heart failure were included in the study. The clinical baseline
characteristics are depicted in Table 1. Mean patient age
was 51 years ± 13 (54; 18–82) with 26 patients (72%) being
male. Pharmacological ACE inhibition was present in 19 pa-
tients (53%) with the remainder serving as ACE
inhibitor-negative controls. ARB administration was an ex-
clusion criterion to avoid confounding on ACE2 expression.
Underlying reason for transplantation included HCM
(n = 12), DCM (n = 8), ICM (n = 8) and ACM (n = 8). Listing
state was urgent in 18 patients (51%), and NYHA functional
Class 3 was the most common class, recorded in 21 patients
(75%). The mean 6MWTD and cardiopulmonary exercise
testing accounted for 314 ± 96 m and for a VO2max of
14.3 ± 7, respectively. Pretransplant inotropic support was
required in 11 patients (31%), and 27 patients (75%) re-
quired some sort of device therapy. Right heart catheteriza-
tion demonstrated mean PCWP, RAP and CI values of
17 ± 6.3 mmHg, 11.2 ± 6.5 mmHg, and 1.69 ± 0.42 l/min/
m2, respectively. Echo accounted for mean LVEF and TAPSE
of 27.5 ± 15.2% and 14.3 ± 4.3 mm, respectively. Mean
NT-proBNP was 4592 ± 3231 pg/mL.
Expression and validation of ACE2 in explanted
human hearts
Figure 1A depicts the workflow and design of the study. The
LV tissue blocks of 36 patients having undergone heart trans-
plantation were retrieved, sectioned and subjected to immu-
nohistochemical staining. LV tissue sections were stained
with antibodies directed against ACE2 and cTnT as well as
ACE2 and SMA and were subsequently quantified and
correlated with clinical baseline characteristics.
Figure 1B visualizes ACE2 expression in explanted human
LV myocardium. Specificity of the staining is confirmed by
neighbouring cardiomyocytes being ACE2 negative compared
with others that account for a strongly positive signal. Spe-
cific ACE2 staining is further corroborated by a lack of signal
upon IgG isotype staining (Figure 1C). Because COVID-19 uses
both ACE2 and the accessory protease TMPRSS2 to gain ac-
cess to human cells, we confirmed co-expression of ACE2
and TMPRSS2 in human cardiomyocytes (Figure 1D). Specific-
ity of TMPRSS2 staining is demonstrated by positivity in some
cardiomyocytes and lack of expression in others. This is fur-
thermore readily shown by a lack of signal upon IgG isotype
staining.
In summary, heterogeneous ACE2 expression can be ro-
bustly visualised by specific immunohistochemical staining,
and a proportion of cardiomyocytes co-expresses ACE2 and
the accessory protease TMPRSS2.
ACE2 expression in human LV myocardium
To demonstrate expression of ACE2 across the LV myocar-
dium, all ACE2-expressing cardiomyocytes were quantita-
tively assessed by manual counting in a blinded fashion
across three images per patient. For validation purposes
and to ensure reproducibility, this was confirmed by a second
independent investigator. The respective Bland–Altman plots
and intraclass correlation coefficients are shown in Figure S1,
confirming sound interobserver variability within a preset
range of 4%.
Quantitative assessment of ACE2 expression in
cardiomyocytes demonstrated that 28.3% ± 22.2% of LV
cardiomyocytes expressed ACE2. Indeed, robust ACE2 expres-
sion in LV myocardium was seen in the majority of patient
samples examined. Group stratification demonstrated that
ACE2 cardiomyocyte positivity was >5% in 31 patients
(86%), >25% in 19 patients (52%) and >45% in 9 patients
(25%) (Figure 2A and 2B).
There were no significant differences between ACE2 ex-
pression in cardiomyocytes (%) across the four different diag-
nostic groups, including HCM, ICM, ACM or DCM (ANOVA
P > 0.05) (Figure 2C). Importantly, we did not detect a signif-
icant difference in the % of ACE2-expressing cardiomyocytes
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in ACE inhibitor-treated patients compared with ACE
inhibitor-negative patients (Figure 2C and 2D).
We next sought to identify clinical characteristics present
prior to transplantation that could predict ACE2 expression
in cardiomyocytes. Correlation analysis demonstrated that
NT-proBNP is significantly positively correlated with % of
ACE2-expressing cardiomyocytes (R2 = 0.37, P = 0.0006).
PCWP obtained from right heart catheterization also had a
significant positive correlation with ACE2 expression in
cardiomyocytes (R2 = 0.13, P = 0.043).
Taken collectively, quantitative analysis demonstrated ro-
bust expression of ACE2 in the myocardium of the majority
of patients. Administration of ACE inhibitors had no effect
on ACE2 expression, but greater levels of NT-proBNP and
PCWP were correlated with greater ACE2 expression in
cardiomyocytes.
ACE2 expression in the blood vasculature
To demonstrate ACE2 expression across the vasculature,
slides were stained with antibodies directed against ACE2
and SMA. SMA is expressed by smooth muscle cells in
the arteriolar wall as well as by pericytes residing in the
wall of the microcirculation. Qualitative assessment of
ACE2-expressing SMA-positive blood vessels demonstrated
a mean value of 5% ± 9% (1%; 0%–32%). In contrast to ex-
pression seen in cardiomyocytes, ACE2 was not detected at
all in the blood vessels of 12 patients (33%) as demon-
strated by the corresponding heatmap (Figure 3A and 3B).
Another 10 patients (28%) showed ACE2 expression in only
0.1%–2% of all SMA + blood vessels. The remainder
(n = 14) demonstrated expression above 2% of all
SMA-expressing vessels, with seven patients (19%) demon-
strating ACE2 expression in 2%–10% and another seven pa-
tients (19%) showing expression in 11%–40% of all
SMA + blood vessels detected.
To further characterize the size of ACE2 positive blood ves-
sels, the diameter of positive vessels was measured. This
demonstrated a range of vessel diameters from 2 to 9 μm,
demonstrating that in this analysis, ACE2 was not expressed
by large calibre blood vessels (Figure 3C). We have addition-
ally performed immunohistochemical staining with antibod-
ies directed against ACE2 and CD31 and confirmed
co-expression in a small subset of blood vessels (Figure 3D).
In line with our analysis of ACE2 expression in
cardiomyocytes, we also did not detect a significant differ-
ence in ACE2 expression in blood vessels between the four
different diagnostic groups (ANOVA P > 0.05). Furthermore,
there was no significant difference in ACE2 expression in
SMA + blood vessels between patients on pharmacological
ACE inhibition and ACE inhibitor-negative patients (Figure
3E and 3F).
In conclusion, ACE2 expression can be found in blood ves-
sels with a diameter ranging from 2 to 9 μm but remains
largely below the % expression levels seen in cardiomyocytes.
Discussion
This study was designed to investigate ACE2 receptor protein
distribution in a quantitative fashion throughout human LV
myocardium and the vasculature in to date the largest series
of its kind. Here, we demonstrated that ACE2 co-localizes
with the accessory protease TMPRSS2 in LV myocardium
and provide a detailed characterization of its distribution
throughout cardiomyocytes, demonstrating marked expres-
sion in this severely diseased cohort. The percentage of ex-
pression in cardiomyocytes was correlated with NT-proBNP
and PCWP, two markers of increased intraventricular pres-
sures. In contrast, the extent of expression in the blood ves-
sels was markedly lower and confined to small calibre
vessels. Importantly, the administration of pharmacological
ACE inhibition did not affect membrane-bound ACE2 receptor
expression at the tissue level.
Although heart failure results in an increase in plasma
ACE2, which predicts disease severity and poor outcome,
few data are available on membrane-bound ACE2.19 Similarly,
in the general population, ACE2 levels predict all-cause and
cardiac mortality with no demonstrable effect exerted by
ACE inhibitors and ARBs on soluble ACE2 expression.27 In
view of the risk of myocarditis in the ongoing COVID-19 pan-
demic, it is essential to understand expression of
membrane-bound ACE2 in vulnerable subgroups such as
heart failure patients and to assess the effects of pharmaco-
logical ACE inhibition.
A recent study by Donoghue and colleagues demonstrated
ACE2 protein expression by immunohistochemistry in endo-
thelial cells and smooth muscle cells only with no difference
seen in failing and non-diseased hearts.28 However, the num-
ber of samples was not stated in this study, which is of partic-
ular importance as our data demonstrate that vascular
expression of membrane-bound ACE2 is heterogeneous in
this cohort, with few demonstrating high expression and a
third with no detectable signal. Furthermore, it is unclear
why ACE2 was not detected in cardiomyocytes by Donoghue
and colleagues, although in our study we used a different pri-
mary antibody and a highly sensitive immunofluorescence
protocol.
Single-cell sequencing data are poorly suited for a compar-
ison with protein data but suggest that only a subset of
cardiomyocytes express ACE2. In non-diseased human hearts,
6.6% of cardiomyocytes expressed ACE2 mRNA.23 In contrast,
in a study by Tucker and colleagues, single-cell nucleus RNA
sequencing demonstrated increased ACE2 expression in pa-
tients with DCM and HCM compared with patients with
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non-diseased hearts.24 There was a non-significant trend for
increased ACE2 expression with pharmacological ACE inhibi-
tion. Nicin and colleagues demonstrated by single-cell se-
quencing that cardiomyocyte ACE2 mRNA expression is
increased in aortic stenosis and heart failure.29 This study fur-
thermore found increased ACE2 expression with administra-
tion of ACE inhibitors but not with ARBs. Bulk sequencing
data demonstrated increased ACE2 mRNA expression in fail-
ing hearts compared with non-diseased hearts with the draw-
back being that it remains unclear which cell types account
for this effect.25 Taken collectively, these sequencing studies
highlight the need to clarify protein responses to validate
how these findings translate from the mRNA level to the pro-
tein level and to elucidate protein expression in the respec-
tive cell types.
Of note, transcriptomic studies have demonstrated high
levels of ACE2 in pericytes and vascular smooth muscle cells.
Our data demonstrate detectable protein expression of
membrane-bound ACE2 in small calibre, pericyte-containing
blood vessels in two-thirds of the patients investigated
(n = 24). However, ACE2 expression was present to a much
lesser degree in the vasculature than seen throughout the
LV in cardiomyocytes, highlighting the need for confirmatory
testing in larger series of patient tissues to put these se-
quencing findings into perspective. The co-expression of
ACE2 and TMPRSS2 in cardiomyocytes seen in this study sup-
ports the notion that COVID-19 can gain access and cause di-
rect cytotoxic damage to cardiomyocytes, which is supported
by post-mortem and clinical studies as well experimental
data.15,16,18
The clinical sequelae of SARS-CoV-2 are well known to also
include vascular complications that are thought to occur at
least in part due to direct viral cytotoxic damage exerted on
the endothelium.30–33 In line with this, post-mortem studies
have identified microthrombi as a key pathologic contributor
to myocardial necrosis.34 Our data demonstrate ACE2 expres-
sion in the LV vasculature, quantitatively in smooth muscle
cells and qualitatively in endothelial cells. In this context,
we have previously demonstrated that hESC-derived smooth
muscle cells can be accessed by SARS-CoV-2 but do not act as
a reservoir for replication.17 The combination of direct endo-
thelial damage and cytotoxicity is likely to result in the clinical
complications seen, including thromboembolic disease, AKI
and neurological disorders.31,35
Finally, our data demonstrate that serum NT-proBNP and
PCWP assessed by right heart catheterization, both markers
of increased intramyocardial pressures, predict greater ACE2
expression in cardiomyocytes. In this context, DCM and
HCM have previously been demonstrated to be associated
with increased ACE2 expression in LV cardiomyocytes.24,36
This is in line with recent data demonstrating that an increase
in remodelling in patients with DCM results in increased ACE2
expression with reverse remodelling reversing this process.37
It is conceivable that the beneficial effects of ACE2 via Ang
1–7 reach a ceiling while ACE2 expression continues to in-
crease. Although this warrants investigation in a prospective
setting, as certain patients with end-stage heart failure exhib-
ited particularly high levels of ACE2 expression, this could
suggest a greater susceptibility to COVID-19.
COVID-19 results in grave cardiovascular morbidity and
mortality in patients with heart failure. Our study suggests
that some of this increased risk may be due to direct interac-
tion between SARS-CoV-2 and cardiomyocytes given the high
expression of membrane-bound ACE2 in cardiomyocytes and
the observed co-expression with TMPRSS2. ESC/AHA/ACC
guidelines for this group of patients suggest to continue
treatment with ACE inhibitors and ARBs and our data are in
support of this because no upregulation of membrane-bound
ACE2 with pharmacological ACE inhibition was demonstrated.
Whether greater levels of membrane-bound ACE2 translate
to greater COVID-19 disease susceptibility warrants investiga-
tion in a prospective setting. Finally, this dataset serves as an
important source of validation for ongoing sequencing
studies.
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Figure S1. Validation of quantitative immunohistochemical
analysis. A) Inter-observer agreement of quantitative assess-
ment of ACE2 + cardiomyocytes. B) Inter-observer agreement
of quantitative assessment of ACE2 + blood vessels. For both
A) and B) Bland–Altman plots exhibits the mean difference as
well as the difference in % of ACE2 + CMs/blood vessels be-
tween the independent measurements of two blinded inves-
tigators. The interobserver agreement was compared for 8
randomly selected images for each of % of
ACE2 + cardiomyocytes (n = 8) and ACE2 + blood vessels
(n = 8). The dotted line shows the mean difference of all read-
outs and the continuous lines exhibit the a priori agreed
limits of allowed deviation in measurements (i.e. 5%). The
Intraclass correlation coefficient (ICC) is shown for all mea-
surements and the corresponding 95%CI in parenthesis.
Table S1. Primary and secondary antibodies used for IHC.
Table S2. Clinical variables significantly correlated with car-
diac ACE2 expression or showing a non-significant trend.
Abbreviations: NT-pro BNP, N-terminal prohormone of brain
natriuretic peptide; PCWP, pulmonary capillary wedge pres-
sure; LVESD, left ventricular end-systolic dimension; BSA,
body surface area; CPEX, cardiopulmonary exercise testing;
ECMO, extracorporeal membrane oxygenation; CABG,
coronary artery bypass grafting; AF, atrial fibrillation.
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